Zenismart-G25 Ampoules contain Glycopyrrolate 25 mcg per 2 ml ampoule, an anticholinergic agent primarily used to reduce salivary, tracheobronchial, and pharyngeal secretions. Glycopyrrolate acts by competitively inhibiting the action of acetylcholine on muscarinic receptors, thereby decreasing secretions and providing antispasmodic effects on smooth muscles. This medication is commonly indicated as a preoperative medication to reduce salivation and respiratory secretions, facilitating intubation and anesthesia management. Additionally, it may be employed in the management of peptic ulcers and to control excessive drooling in certain neurological disorders. Zenismart-G25 is administered via intravenous or intramuscular injection, with dosage tailored according to clinical indication and patient response. Caution is advised in patients with glaucoma, prostatic hypertrophy, or urinary retention due to potential anticholinergic side effects. Common adverse reactions include dry mouth, blurred vision, tachycardia, and urinary retention. Use during pregnancy and lactation should be under strict medical supervision. Proper aseptic technique is essential during administration to prevent infection. Zenismart-G25 Ampoules should be stored at controlled room temperature, protected from light and moisture. Always consult healthcare professionals before use to ensure appropriate dosing and monitoring.